$DYN

Dyne Therapeutics, Inc. (DYN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion o

Dyne Therapeutics (DYN) reported 12-month data from its Phase 1/2 ACHIEVE trial of z-basivarsen for Myotonic Dystrophy Type 1, showing functional improvements across multiple measures. The company expects topline data from the registrational expansion cohort in Q1 2027, with a potential U.S. Accelerated Approval submission in Q3 2027. The mean baseline vHOT in the ACHIEVE REC is 8.3 seconds.

Dyne Therapeutics (DYN) shares fell after a recent rally driven by positive clinical data and a competitor's trial failure. Investors are taking profits, but the company's low debt and cash runway until 2028 provide financial flexibility. Risks include cash burn, no approved products, and dependence on future financing.

Dyne Therapeutics (DYN) shares dropped 10% after-hours on plans to raise $300M via a stock offering. This follows FDA acceptance of its z-rostudirsen application for Duchenne muscular dystrophy, with a decision expected by January 2027. The company aims to use proceeds for clinical development and commercial infrastructure. DYN stock is up 22% year-to-date.

Global markets are mixed, with stocks and bonds falling as crude oil surges. The 10-year T-note yield rose to a 2.75-year high of 4.849%. Chipmakers and energy producers gained, while ServiceTitan (TTAN) fell over 30% after a larger-than-expected Q2 loss. Casys General Stores (CASY) dropped 14% due to a lower-than-expected Q1 gross margin. Meta Platforms (META) rose 6% on positive AI assistant reviews.

Morgan Stanley maintained an Overweight rating on Dyne Therapeutics (DYN) but lowered its price target from $45 to $36. The company has a market cap of $3.65B, a GF Score of 34, and significant insider selling. Analysts remain cautious due to profitability challenges and market conditions.

Novartis (NVS) shares fell 14% after a late-stage trial for del-desiran in myotonic dystrophy type 1 failed its primary test, marking its second trial failure in a week. The drug showed activity on secondary measures, and the company will review data. Dyne Therapeutics (DYN) and Sarepta Therapeutics (SRPT) also declined in sympathy.

Dyne Therapeutics (DYN) stock fell 23% to $18.60 on Tuesday, despite plans to present one-year clinical data from its Phase 1/2 ACHIEVE trial for myotonic dystrophy type 1. The company will share six- and 12-month data from the trial and updated safety data at upcoming medical meetings. Dyne's 52-week range is $11.92 to $27.31.

Dyne Therapeutics (DYN) shares fell 28% after Novartis' Phase III trial for a similar drug failed. Dyne's stock dropped to $17.50, reflecting investor concerns about its pipeline. The company has no revenue, and insiders have sold $168.4M in shares over 12 months. Dyne's GF Score is 34/100, indicating financial and operational challenges.

Jefferies rated Dyne Therapeutics (DYN) Buy with a $50 target despite a 26% selloff after Novartis' DM1 trial failure. Dyne, a biotech firm, focuses on neuromuscular disease treatments. Its GF Score is 34/100, with strong financial health but weak profitability. Insiders sold $168.4M in shares. The company has no revenue, trading at $24.27 with a $4.53B market cap.